In myeloma, sensitivity to venetoclax in vitro is mainly observed in plasma cells harboring the t (11;14) translocation, a molecular subgroup associated with high BCL2 and low MCL1/BCL-XL expression [7]. This evidence concerns the gene BCL2L1 and plasma cell myeloma.